会员体验
专利管家(专利管理)
工作空间(专利管理)
风险监控(情报监控)
数据分析(专利分析)
侵权分析(诉讼无效)
联系我们
交流群
官方交流:
QQ群: 891211   
微信请扫码    >>>
现在联系顾问~
热词
    • 83. 发明授权
    • 적혈구에 활성 성분을 내재화시키는 용해/재봉합 방법 및 장치
    • 用于在红细胞中掺入活性成分的裂解/再密封过程和装置
    • KR101332733B1
    • 2013-11-25
    • KR1020077004994
    • 2005-08-04
    • 에리테끄 파르마
    • 고드프랭,얀느
    • A61K9/50A61P35/02A61K31/6615A61K38/50
    • C12M47/06A61K9/5068A61K31/6615A61K35/18
    • 활성 성분, 특히, 아스파라기나아제 또는 이노시톨 헥사포스페이트를 적혈구에 내재화하는 용해/재봉합 방법 및 장치가 개시된다. 활성 성분을 포함하는 적혈구를 제조하는 용해/재봉합 방법으로서, 상기 방법은 하기 단계들을 포함한다: (1) - +1 내지 +8℃로 냉장되고 65%와 동일하거나 또는 그 이상의 적혈구 용적율을 갖는 등장액에 현탁된 혈구 농축액을 넣는 단계, (2) - 상기 동일한 혈구 농축액으로부터의 적혈구 시료, 바람직하게는 상기 단계 (1)에서 수득된 현탁액의 시료에 대해 삼투압 취약성을 측정하는 단계, (3) - +1 내지 +8℃로 일정하게 유지되는 온도에서, 상기 동일한 챔버 내부에서 용해 및 상기 활성 성분의 내재화를 수행하는 단계로서, 65% 이상의 적혈구 용적율을 갖는 적혈구 현탁액 및 +1 내지 +8℃로 냉장된 저장성의 용해 용액을 투석 카트리지에서 순환시키는 단계를 포함하고; 상기 용해 파라미터는 상기 측정된 삼투압 취약성에 따라 조절하는 것인 단계; 및 (4) - 제2 챔버에서 고장액에 의해 +30 내지 +40℃의 온도에서 재봉합 절차를 수행하는 단계.
      용혈, 아스파라기나아제, 적혈구 용적율, 저산소증, 이노시톨 헥사포스페이트, 용해/재봉합
    • 86. 发明公开
    • 포스포릴콜린 유사기 함유 화합물, 이의 제조방법, 및 이의 용도
    • 具有磷酰氯类的化合物,其制备方法及其用途
    • KR1020120119805A
    • 2012-10-31
    • KR1020110038004
    • 2011-04-22
    • 주식회사 케이씨아이
    • 윤광호
    • C07F9/10A61K31/6615A61K8/55A61P29/00
    • C07F9/113A61K8/553A61K31/6615A61Q19/08
    • PURPOSE: A choline phosphate like group containing compound or a manufacturing method thereof is provided to enhance moisture maintenance, anti-inflammation effects or anti-wrinkle effects. CONSTITUTION: A choline phosphate like group containing compound is represented by chemical formula(1). The choline phosphate like group containing compound is panthenyl phosphorylcholine represented by chemical formula (2). The choline phosphate like group containing compound is racemate. The optical activity of the choline phosphate like group containing compound is D form. A manufacturing method of choline phosphate like group containing compound comprises the following steps: synthesizing an intermediate represented by chemical formula 5; and synthesizing an intermediate containing phosphorylcholine represented by the chemical formula(1). The third amine represented by the chemical formula(6) is trimethylamine, dimethylmethanolamine or dimethylethanolamine.
    • 目的:提供含磷酸胆碱基的化合物或其制造方法以增强水分维持,抗炎作用或抗皱纹效果。 构成:含磷酸胆碱基的化合物由化学式(1)表示。 含磷酸胆碱基化合物是由化学式(2)表示的泛酸磷酰胆碱。 含磷酸胆碱的化合物是消旋体。 含磷酸胆碱基的化合物的光学活性为D型。 含磷酸胆碱基的化合物的制造方法包括以下步骤:合成由化学式5表示的中间体; 合成由化学式(1)表示的含有磷酸胆碱的中间体。 由化学式(6)表示的第三胺是三甲胺,二甲基甲醇胺或二甲基乙醇胺。
    • 89. 发明公开
    • 이노시톨 폴리포스페이트 유도체 및 그의 사용 방법
    • 异吲哚多磷酸盐衍生物及其使用方法
    • KR1020060028630A
    • 2006-03-30
    • KR1020057013708
    • 1997-09-19
    • 더 리전트 오브 더 유니버시티 오브 캘리포니아이놀로직, 인크.유니버시티 오브 캘리포니아, 샌디에고
    • 트레이노어-카프란알렉시스슐쯔카르스덴뢰머슈테판슈타틀러크리스토프루돌프마르코
    • A61K31/685A61K31/66A61K31/015A61P1/14
    • A61K31/6615A61K31/683C07F9/117
    • The present invention provides compositions that are cell permeable antagonists of inositol polyphosphates. In addition, the invention provides methods for enhancing chloride ion secretion from a cell by contacting the cells with cell permeable antagonists of inositol polyphosphates. The invention also provides methods for enhancing chloride ion secretion in an individual by administering cell permeable antagonists of inositol polyphosphates to the individual. The invention additionally provides methods for alleviating a sign or symptom associated with cystic fibrosis in an individual by administering a cell permeable antagonist of inositol polyphosphates to the individual. The invention also provides compositions that are cell permeable agonists of inositol polyphosphates. In addition, the invention provides methods for decreasing chloride ion secretion from a cell by contacting the cell with cell permeable agonists of inositol polyphosphates. The invention also provides methods for decreasing chloride ion secretion in an individual by administering cell permeable agonists of inositol polyphosphates to the individual. The invention additionally provides methods for alleviating a sign or symptom associated with secretory diarrhea in an individual by administering cell permeable agonists of inositol polyphosphates to the individual.
    • 本发明提供了作为肌醇多磷酸盐的细胞渗透性拮抗剂的组合物。 此外,本发明提供了通过使细胞与肌醇多磷酸盐的细胞可渗透的拮抗剂接触来提高细胞中氯离子分泌的方法。 本发明还提供了通过向个体施用肌醇多磷酸盐的细胞可渗透的拮抗剂来增强个体中的氯离子分泌的方法。 本发明还提供了通过向个体施用肌醇多磷酸盐的细胞可渗透拮抗剂来减轻个体中与囊性纤维化相关的征兆或症状的方法。 本发明还提供了作为肌醇多磷酸盐的细胞渗透性激动剂的组合物。 此外,本发明提供了通过使细胞与肌醇多磷酸盐的细胞可渗透的激动剂接触来减少细胞的氯离子分泌的方法。 本发明还提供通过向个体施用肌醇多磷酸盐的细胞可渗透的激动剂来减少个体中的氯离子分泌的方法。 本发明另外提供了通过向个体施用肌醇多磷酸盐的细胞可渗透的激动剂来减轻个体中与分泌性腹泻相关的征兆或症状的方法。
    • 90. 发明公开
    • N-아실라이소포스파티딜콜린 화합물의 제조 방법
    • 生产N-羟基磷脂酰胆碱化合物和含有相同用于治疗代谢性骨髓疾病的药物组合物
    • KR1020030048373A
    • 2003-06-19
    • KR1020020079874
    • 2002-12-13
    • 전길자김홍희이장희한소엽
    • 전길자이장희한소엽김홍희이은희김영아곽한복
    • A61K31/661
    • C07F9/10A61K31/14A61K31/16A61K31/6615C07F9/091
    • PURPOSE: Provided is a process of preparing an N-acyllysophosphatidylcholine compound which is excellent in inhibition of differentiation of osteoclast cells and has no toxicity. A pharmaceutical composition containing the N-acyllysophosphatidylcholine compound is useful in the prevention and treatment of metabolic bone disease. CONSTITUTION: A pharmaceutical composition for the prevention and treatment of metabolic bone disease contains N-acyl-o-phosphocholine-L-serine methylester compound of formula(1) or a pharmaceutically acceptable salt thereof alone or together with a pharmaceutically acceptable carrier. In formula, R is C14-20 saturated for unsaturated fatty acid. The metabolic bone disease is any one selected from the group consisting of osteoporosis, bone metastatic cancer lesions, a tumor formed primarily in bones, rheumatoid or degenerative arthritis, periodontal disease, alveolar bone resorption disease, inflammatory bone resorption disease and Paget's disease.
    • 目的:提供抑制破骨细胞分化且无毒性的N-酰基磷脂酰胆碱化合物的制备方法。 含有N-酰基磷脂酰胆碱化合物的药物组合物可用于预防和治疗代谢性骨病。 构成:用于预防和治疗代谢性骨疾病的药物组合物单独或与药学上可接受的载体一起含有式(1)的N-酰基-O-磷酸胆碱-L-丝氨酸甲酯化合物或其药学上可接受的盐。 在式中,对于不饱和脂肪酸,R为饱和的C14-20。 代谢性骨病是选自骨质疏松症,骨转移性癌症病变,主要在骨形成的肿瘤,类风湿性关节炎,退行性关节炎,牙周病,牙槽骨吸收疾病,炎性骨吸收疾病和佩吉特氏病等中的任意一种。